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Background: Amplification of the MYCN oncogene is the most unfavorable genetic
factor in neuroblastoma patients. However, knowledge about the clinical impact of
low-level multiplication of MYCN is still insufficient. Therefore, we aimed to investigate
the disease course in patients with different copy number status of MYCN.
Materials and Methods: We examined 105 children diagnosed with neuroblastoma
from 2010 to 2018 in five pediatric oncology centers in Poland. We determined the
MYCN status at diagnosis by the interphase FISH examination and assessed the clinical
outcome in patients.
Results: A total of 35% of tumors presented with chromosome 2 numerical changes,
20% had MYCN amplification and 16% revealed 2p gain. Unexpectedly, we observed
very low overall survival and event free survival (EFS) rates in neuroblastomas with 2p
gain, which were comparable with patients with MYCN amplification.
Conclusions: The 2p gain alteration should be reported as a strong unfavorable
prognostic marker in neuroblastoma patients.
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INTRODUCTION
Neuroblastoma (NB) is the most common (6–8%) solid extracranial tumor of childhood that is
responsible for 50% of all childhood cancer-related deaths. The unfavorable prognosis with high
risk of relapse and death in NB correlates with age over 18 months at diagnosis, advanced disease
stage, and established genetic markers. Amplification of the MYCN oncogene (MNA) is the most
robust genetic factor correlated with poor clinical outcome and can be found in about 16–20% of
NB cases (and up to 40% in high-risk tumors) (1–5). Gain of theMYCN gene locus on the short arm
of chromosome 2 (2p24) can also be found in NB cells (6–8). Since the oncogeneMYCN is involved
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in all facets of metastasis: cell adhesion, motility, invasion,
and degradation of extracellular matrix, it is crucial to
accurately estimate the MYCN status at NB diagnosis (4,
9). The recommended technique for counting MYCN copies
is fluorescence in situ hybridization (FISH) (2, 10). The
international guidelines for FISH analysis clearly stratify
between high-level copy number change of MYCN (MNA),
low-level multiplication of (MYCN gain and 2p gain) and
numerical changes and no multiplication of MYCN (normal
status) (1, 2).
Contrary to MNA, little is known about the importance of
low-level MYCN variants (including 2p gain) as prognostic
factors in NB patients (6, 10–12). Therefore, the aim
of this study was to assess the clinical impact of such
variants in relation to normal MYCN status and MNA
and to evaluate the potential, practical benefits of routine
testing for low-level MYCN variants in all patients with
NB. Additionally, for the first time we present clinical
and tumor biological features in a population of Polish
NB patients.
FIGURE 1 | Examples of copy number status of MYCN gene in NB tumors detected by interphase FISH examination (probes: red-MYCN locus-2p24.3 and
green-control locus-2q11.2): (A) normal, (B) chromosome 2 numerical changes, (C) 2p gain, (D) amplification.
TABLE 1 | Clinical data for the study group.









Patient age >18 months 14 (67%) 12 (46%) 10 (59%) 12 (67%)
<18 months 7 (33%) 14 (54%) 7 (41%) 6 (33%)
INSS** 1 5 (24%) 6 (23%) 3 (18%) 2 (11%)
INSS 2 5 (24%) 2 (8%) 0 (0%) 0 (0%)
Disease stage INSS 3 6 (29%) 10 (38%) 3 (18%) 3 (17%)
INSS 4 3 (14%) 6 (23%) 8 (47%) 12 (67%)
INSS 4S 2 (9%) 2 (8%) 3 (18%) 1 (6%)
High 4 (19%) 5 (19%) 7 (41%) 16 (89%)
Risk group Intermediate 6 (29%) 15 (58%) 5 (29%) 2 (11%)
Low 11 (52%) 6 (23%) 5 (29%) 0 (0%)
Metastases 5 (24%) 8 (31%) 11 (65%) 13 (72%)
Patient outcome Relapse 8 (38%) 7 (27%) 5 (28%) 5 (29%)
Death 2 (9.5%) 2 (8%) 6 (35%) 5 (28%)
*MNA, MYCN amplification; **INSS, International Neuroblastoma Staging System.
MATERIALS AND METHODS
We enrolled all patients diagnosed with NB between 2010
and 2018 year in five regional pediatric oncology centers
in Poland. Patients were treated according to the current
protocols of European International Society of Pediatric
Oncology Neuroblastoma Group. Clinical features assessed
included the age at diagnosis, disease stage, as well as the
presence of metastases and relapses. We collected data about
biological profiles of NB tumors, including the status of MYCN
and ALK locus (ALK is located in close vicinity of MYCN
and co-amplification of these two genes was observed) (13).
Additionally, we assessed the presence of 11q23 deletion,
which was reported to have unfavorable prognostic importance
in NB and to be negatively correlated with MNA (4, 6,
14, 15). This study was carried out in accordance with the
recommendations of The Ethics Committee of Jagiellonian
University Medical College, Krakow, Poland. All subjects gave
written informed consent in accordance with the Declaration
of Helsinki.
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We determined the MYCN status at diagnosis by means
of interphase FISH examination according to international
guidelines (1, 16, 17). The dual-color set of fluorescence probes
N-MYC (MYCN) Amplification (Cytocell, Cambridge, UK) was
hybridized to tumor imprint slides according to manufacturer’s
protocol. The NB patients were classified as having tumors with:
- MNA (>4-fold increase ofMYCN signals in comparison with
the reference probe),
- 2p gain (1–2 more of MYCN signals in comparison with the
reference probe),
- chromosome 2 numerical changes (equal number of MYCN
and reference signals corresponding to numerical alterations
of chromosome 2),
- normal MYCN status (wild-type, two MYCN copies and two
reference signals).
We used the interphase FISH method for detection of
11q23 deletion [KMT2A(11q23)/SE11 probe; Leica Biosystems,
Wetzlar, DE] and, additionally, if archival tumor imprint slides
were available, theALK gene status was assessed (ALKBreakapart
probe; Cytocell, Cambridge, UK).
Finally, we compared the disease outcome in specific
subgroups of patients with different copy number status of
MYCN gene. Descriptive statistics, the Fisher’s exact test and
Kaplan–Meier curves were implemented, and Cox’s proportional
hazards regression model was used for multivariate analysis.
TABLE 2 | The status of 11q23 deletion in the study group.









11q23 deletion 1 (8%) 2 (11%) 3 (30%) 2 (15%)
*MNA, MYCN amplification.
RESULTS
We enrolled 105 NB patients. In 37 (35%) cases chromosome
2 numerical changes were observed in tumors, whereas in 21
children (20%) MYCN amplification and in 17 (16%) 2p gain
were found. A group of 30 (29%) patients showed normalMYCN
status (Figure 1).
A total of 82 NB patients completed the 5-years clinical
observation period or died prior to the 5 year time point since
diagnosis. The biological markers of interest and the clinical
observational data for this group of children are listed in Table 1.
We found an unexpectedly high percentage of cases with NB
stage 4 in children with 2p gain. This was significantly higher than
in patients with MYCN normal status (p = 0.03 in Fisher’s exact
test). We observed that the incidence of patients with stage 4S
was about two times higher in the group of 2p gain than in other
subgroups, but the differences were not statistically significant.
We also found a statistical trend regarding the higher percentage
of deaths in patients with 2p gain (p = 0.06). Furthermore,
no statistically significant differences were found regarding the
relapse rate.
We observed a slightly higher frequency of 11q23 deletion
in patients with 2p gain in comparison with other groups
(Table 2). However, the differences also did not reach statistical
significance. Finally, archival tumor imprint slides for ALK gene
status assessment were available in a subset of 10 patients with 2p
gain and 11 patients with MNA. ALK co-gain was observed in six
cases with 2p gain (60%) and ALK co-amplification was detected
in one case of MNA.
The 5-year overall survival rate (OS) for patients with MNA
and 2p gain reached 69 and 52%, respectively, whereas in patients
with numerical changes of chromosome 2 it was similar to
normal MYCN status (95 and 94%, respectively, Figure 2). In
our cohort, patients with 2p gain in NB tumors had very low
OS that was comparable to the MNA group and significantly
lower than in patients with normal MYCN status (p = 0.03;
FIGURE 2 | Kaplan–Meier estimates of (A) 5-OS with statistically significant differences, and (B) 5-EFS without statistically significant differences between specific
subgroups in relation to copy number status of MYCN gene.
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FIGURE 3 | Kaplan–Meier estimates of (A) 5-OS and with statistically significant differences in high-risk disease group of NB patients and (B) 5-EFS without
statistically significant differences between specific subgroups in relation to copy number status of MYCN gene in high-risk disease group of NB patients; (C) 5-OS in
MNA subgroup and (D) 5-OS in 2p gain subgroup in relation to disease stage; (E) 5-OS in MNA subgroup and (F) 5-OS in 2p gain subgroup in relation to patients age.
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Kaplan–Meier statistics). We observed a similar trend for the
5-year event free survival (EFS), but the differences did not reach
statistical significance (Figure 2). 2p gain decreased survival
rate specifically among patients with high-risk disease, disease
stage 4 and aged over 18 months (Figure 3). The group of
children with chromosome 2 numerical changes did not differ
significantly from those with normal MYCN status with regard
to disease outcome.
Although none of the statistical tests attempted for Cox’s
proportional hazard regression analysis reached statistical
significance, we would like to summarize our approach in
order to indicate where important conclusions could be reached
with an increase in sample size. MYCN status was compared
for 5-year OS and EFS (normal status as a reference). MNA,
2p gain, and chromosome 2 numerical changes gave hazard
ratios (HR) of 2.46 (0.27–22.51, 95% CI, p = 0.43), 3.76
(0.44–32.50 95% CI, p = 0.23, and 1.49 (0.13–16.63, 95%
CI, p = 0.75) for 5-year OS. Comparing NB disease stages
1, 2, 3, 4, and 4s (in accordance with INSS—International
Neuroblastoma Staging System), was also carried out as was
assessing the impact of age. We also tested for interaction
between MYCN status and INSS, MYCN status and age, and all
three together, but again none of the interacting factors reached
statistical significance.
DISCUSSION
The incidence of 2p gain aberration that we observed in
our cohort was relatively high (16%) in comparison to other
European populations [3% as reported by Campbell et al. (18),
6% as submitted Cohn et al. and Spitz et al. (11, 12) and 13–
14% as announced Jeison et al. and Stallings et al. (6, 7)],
but comparable to Asian populations [∼15% as described by
Souzaki et al. (10)]. These differences may be related to the
number of cases in each study group or the biological origin
of the analyzed samples [some researchers evaluated the MYCN
gene status in tumor specimens and bone marrow aspirates,
without distinguishing between primary and metastatic sample
origin (6, 12, 18)].
Our results show that the presence of 2p gain in patients
with NB is frequently co-incident with advanced disease stage
at diagnosis, confirming other previous observations (6, 10, 11).
However, in contrast to MNA, NB tumors with 2p gain do
not present with locus-specific, highly increased expression of
MYCN (12). This indicates the existence of different mechanisms
present in both groups of patients. It may be that 2p gain
leads to a partial trisomy of the short arm of chromosome 2,
which contains not only the MYCN oncogene but also several
other genes involved in carcinogenesis (ADAM17, ALK, BCL11A,
DDX1, EML4, EPCAM, EPAS1, E2F6, FANCL, GALM, GREB1,
ID2, MSH2, MSH6, NCOA1, NOTO, REL, RHOB, ROCK2,
RRM2, SDC1, TPO, XPO1)1,2. Multiplication of the above-
listed genes in addition to the MYCN oncogene could be
1http://www.cancerindex.org
2http://atlasgeneticsoncology.org
responsible for worsening of the clinical prognosis in patients
with NB.
Previous reports suggested that ALK copy number
multiplication, if occurring concurrently with MYCN,
significantly reduces patients survival especially for the
intermediate- and high-risk group (13, 19), and that 2p gain
tumors encompassing the ALK locus also associate with worse
outcome (20). The presence of additional ALK gain in our
“2p gain” subgroup might partially explain worse disease
outcome in some of these patients. However, the individual
contribution of the gain of ALK and other above-mentioned
genes to disease outcome should be investigated in larger cohorts
of NB patients.
In our study, the 2p gain corresponded with decreased average
5-year OS and EFS, similarly to the group of patients with
MNA (the 5-year OS was even slightly lower in the subgroup
with 2p gain). This is in line with the results of Jeison et al.
(6) and Campbell et al. (18). However, the above-mentioned
very advanced disease stage at the time of diagnosis in many of
our 2p gain-patients seems to explain the frequently observed
unfavorable disease outcome.
Moreover, Stiglani et al. (21) reported that NB tumors with
structural chromosome changes, such as the prognostically
independent and unfavorable 11q23 deletion, have a greater
tendency to accumulate additional genetic instability. Therefore,
the potential coexistence of structural alterations like 2p
gain and 11q23 deletion in NB cells should be considered
(6, 7, 10–12). However, the frequency of 11q23 deletion
was relatively low in our material, which makes detailed
analysis difficult. On the other hand, Jeison et al. did
not find significant differences in the 5-year OS between
subgroups of 2p gain patients with or without coexistence
of 11q deletions in tumor cells (6). In contrast, Cohn et al.
postulated that 2p gain is not an independent prognostic
factor (11).
In conclusion, our results indicate that the presence of 2p
gain in patients with NB is an unfavorable prognostic marker,
especially in patients with high-risk disease, similar to MYCN
amplification. It seems that 2p gain correlates with decreased
OS and, potentially might decrease EFS. Further studies in
larger populations of patients are necessary to verify the clinical
significance of 2p gain. If our results are confirmed, patients with
2p gain might require more intensive therapy.
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